TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01434316
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06767982
Drug: Bacillus Calmette-Guerin (BCG)
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients
Study: NCT04083599
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT04083599
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT04083599
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT04083599
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT04083599
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT04083599
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT04083599
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous
Study: NCT04083599
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT04267887
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04267887
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04267887
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04121676
Drug: Botensilimab
Normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CTLA-4 Monoclonal Antibody
Study: NCT00313079
Drug: MAb 216
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 1.25mg/kg intravenous with dose escalation
Study: NCT00313079
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage: 1.5mg/m2 intravenous weekly X 4
Study: NCT00704132
Drug: Comparator: sitagliptin phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin tablet 100 mg, administered once daily before the morning meal.
Study: NCT02544529
Drug: Echothiophate Iodide 0.03% Ophthalmic Solution
DrugBank: Echothiophate (DB01057)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one drop to each eye three times per week for 18 weeks
Study: NCT02544529
Drug: Carboxymethylcellulose Sodium (0.5%)
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop to each eye three times per week for 18 weeks
Study: NCT03477175
Drug: E7080
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Administration.
Study: NCT03477175
Drug: Comparator Drug: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per parent study.
Study: NCT03908437
Drug: buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs
Study: NCT06411067
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly injection of erenumab for fibromyalgia
Study: NCT06411067
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly injection of 0.9% saline for control
Study: NCT02115594
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02115594
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04294966
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administering dextrose to healthy volunteers for our placebo group
Study: NCT04294966
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
Study: NCT04432987
Drug: Pulmozyme
Normalized name: Pulmozyme
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days
Study: NCT04678492
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID
Study: NCT04678492
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID
Study: NCT04678492
Drug: Bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
Study: NCT04678492
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
Study: NCT03593226
Drug: AGI-134
Normalized name: AGI-134
DrugBank: AGI-134 (DB19005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
Study: NCT01038778
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04678492
Drug: Furazolidone
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
Study: NCT01055821
Drug: pegylated interferon and ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 48 weeks
Study: NCT00515502
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler
Study: NCT02436265
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone
Study: NCT02436265
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine only
Study: NCT00639873
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 or 4 mg/kg/day for 7 days
Study: NCT01059565
Drug: AZLI
Normalized name: Bazlitoran
DrugBank: Bazlitoran (DB14990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
Study: NCT02525874
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial oral dose for 7 days with maintenance dose thereafter
Study: NCT00574587
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
Study: NCT00574587
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 weekly for 12 weeks
Study: NCT00574587
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
Study: NCT00006213
Drug: BMS-214662
Normalized name: BMS-214662
DrugBank: BMS-214662 (DB12234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01692782
Drug: SEP-225289
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-225289 4mg once daily
Study: NCT01692782
Drug: SEP-225289
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-225289 8mg once daily
Study: NCT02645981
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
Study: NCT02645981
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control
Study: NCT02732938
Drug: PF-04136309
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04136309 oral dosing
Study: NCT02732938
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel IV dosing
Study: NCT02732938
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine IV dosing
Study: NCT03252587
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04052204
Drug: avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigational fully human anti-PD-L1 monoclonal antibody
Study: NCT04052204
Drug: Bempegaldesleukin
Normalized name: Bempegaldesleukin
DrugBank: Bempegaldesleukin (DB15140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational CD122-biased cytokine agonist
Study: NCT04052204
Drug: talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor
Study: NCT04052204
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: androgen receptor inhibitor
Study: NCT02486484
Drug: ziv-aflibercept
Normalized name: Ziv-Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: zaltrap injection
Study: NCT00095225
Drug: Avastin (bevacizumab)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00095225
Drug: Tarceva (erlotinib HCl)
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03263429
Drug: Irinotecan Hydrochloride (phase I only)
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein
Study: NCT00436657
Drug: CHPP of Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
Study: NCT03275285
Drug: isatuximab SAR650984
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03275285
Drug: carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03275285
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous
Study: NCT03914612
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03914612
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04341116
Drug: TJ003234
Normalized name: TJ003234
DrugBank: TJ003234 (DB16470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive a single infusion
Study: NCT02194270
Drug: Ambroxol hydrochloride - soft pastille
Normalized name: ambroxol hydrochloride
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02194270
Drug: Ambroxol hydrochloride - syrup - low dose
Normalized name: ambroxol hydrochloride
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02194270
Drug: Ambroxol hydrochloride - syrup - high dose
Normalized name: ambroxol hydrochloride
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01803074
Drug: BMS-955176
Normalized name: BMS-955176
DrugBank: BMS-955176 (DB15193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-955176
Study: NCT01803074
Drug: Placebo matching with BMS-955176
Normalized name: BMS-955176
DrugBank: BMS-955176 (DB15193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching with BMS-955176
Study: NCT01803074
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Atazanavir
Study: NCT01803074
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir
Study: NCT01803074
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir
Study: NCT01803074
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine
Study: NCT02212574
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
Study: NCT02212574
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
Study: NCT02212574
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
Study: NCT02212574
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
Study: NCT02212574
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
Study: NCT01710176
Drug: epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710176
Drug: gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01710176
Drug: trabectedin 1.3 mg/m2
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01710176
Drug: high-dose ifosfamide 14 g/m2, given in in 14 days
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710176
Drug: etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01710176
Drug: gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03788837
Drug: ILOPROST
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
Study: NCT03788837
Drug: NaCl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
Study: NCT02659293
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21
Study: NCT02659293
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16
Study: NCT02659293
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22
Study: NCT02659293
Drug: Lenalidomide (Control)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28
Study: NCT03691493
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03691493
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03691493
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IM
Study: NCT03691493
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03691493
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03691493
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01909453
Drug: vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets in bottles or blisters 240 mg
Study: NCT04338399
Drug: Buparlisib & Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigation drug plus paclitaxel
Study: NCT03680456
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maximum of 750mg in U.S. is given, maximum of 1000mg in EU
Study: NCT03680456
Drug: Crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an equivalent volume dose of Natriumchlorid is administered
Study: NCT03626688
Drug: Ralinepag
Normalized name: Ralinepag
DrugBank: Ralinepag (DB12462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT03227861
Drug: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
Normalized name: (-)-FTC
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.